系统性硬化症中的嘌呤能信号传导
本文综述了细胞外嘌呤代谢与嘌呤能信号传导在系统性硬化症(SSc)分子病理中的作用,涉及血管病变、免疫失调和纤维化,并探讨了靶向嘌呤能信号传导作为SSc新治疗选项的转化应用。
要点
- 嘌呤能信号传导可能参与SSc血管病变、免疫失调和纤维化的病理生理过程。
- 细胞外嘌呤在SSc中失调,可加剧血管病变、诱发血小板功能障碍并导致免疫失调。
- 嘌呤能信号传导组分在多种疾病模型中促进器官和组织纤维化。
核心结论
- 嘌呤能信号传导通路可能与SSc多种疾病表现的病理生理相关,靶向该通路有望为SSc提供新治疗选择。
研究设计与样本
- 综述,概述细胞外嘌呤代谢在嘌呤能信号传导中的作用及其与SSc分子病理的联系。
主要发现
- 细胞外嘌呤是强效信号介质,在SSc中已显示失调。
- 嘌呤可加剧血管病变并诱发血小板功能障碍,同时参与免疫失调。
- 嘌呤能信号传导组分在多种疾病模型中进一步促进器官和组织纤维化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SSc is a chronic autoimmune rheumatic disease that involves numerous organs and presents major management challenges. The histopathologic hallmarks of SSc include vasculopathy, fibrosis and autoimmune phenomena involving both innate and adaptive immune systems. Purinergic signalling is a pathway that may be implicated in the pathophysiology of several of these disease manifestations. Extracellular purines are potent signalling mediators, which have been shown to be dysregulated in SSc. As examples, purines can exacerbate vasculopathy and provoke platelet dysfunction; as well as contributing to immune dysregulation. Elements of purinergic signalling further promote organ and tissue fibrosis in several disease models. Here, we provide an overview of extracellular purine metabolism in purinergic signalling and link disorders of these to the molecular pathology of SSc. We also discuss targeting the purinergic signalling and explore the translational applications for new therapeutic options in SSc.
引用
- Höppner J, Bruni C, Distler O, et al. Purinergic signalling in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 34849624. doi:10.1093/rheumatology/keab859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。